The Swiss voice in the world since 1935

Novartis app for opium addicts gets US approval

Novartis banner
The reSET-O prescription medical application is a 12-week software application providing cognitive behavioral therapy as a support to outpatient treatment. Keystone

Sandoz Inc., a division of Swiss pharmaceutical giant Novartis, and US company Pear Therapeutics announced this week that the the U.S. Food and Drug Administration (FDA) has approved an app that can be prescribed to help treat opium addicts.

For patients 18 years or older who are currently under the supervision of a clinician, reSET-O is indicated as a prescription-only mobile medical application, Novartis noted in a media statementExternal link

As a digital therapist, the app is intended to protect patients from relapses with interactive dialogues.  Every day, approximately 115 Americans die after overdosing on opioids. 

“Digital technologies and data science have incredible potential to unlock the next chapter of medical innovation and to help individuals finally take control of their own health in a meaningful way,” said Sandoz CEO Richard Francis. “New digital therapeutics such as reSET-O also have the potential to fundamentally change how patients interact with their therapies and thus improve patient outcomes. At Sandoz, we are proud to be a joint pioneer in this exciting new field.”

The Novartis generics subsidiary SandozExternal link is responsible for marketing the application prescribed by the physician. In the spring, Sandoz signed a cooperation agreement with Pear TherapeuticsExternal link. Sandoz says it hopes to be able to charge $15 (CHF15) per month for the app. However, the price is not yet definite, the NZZ am Sonntag reported.External link

The US regulatory authority has been convinced by its success. Over 12 weeks, 170 patients participated in an opiate withdrawal program. All received a replacement drug. However, 82.4% of those who used the app remained in the program. In the group without a supportive app, only 68.4% managed the full three months, the FDA reported in a press release.

In the United States, 48.5 million people are addicted to drugs. About 18.5% of the adult population consume illegal drugs such as heroin or abuse legal substances such as painkillers. Alcoholics are not included in the figures.

The statistics also reflect the devastating opium dependence of broad sections of the population. The problem is widely blamed on the lax prescription practice of new, supposedly non-addictive painkillers since the 1990s. The “economic burden” of this epidemic amounts to $78.5 billion annually, according to the Centers for Disease Control and PreventionExternal link.

Popular Stories

Most Discussed

News

Only one in five people attend a religious service at Easter

More

Just one in five Swiss attend a religious service at Easter

This content was published on Only one in five people in Switzerland attend a religious service during the Easter period or give up meat or alcohol for at least one day of fasting. Around 25% of those polled see Easter primarily as a family holiday, according to the survey.

Read more: Just one in five Swiss attend a religious service at Easter
Posters condemning Stephan Schmidheiny's role in asbestos deaths in Italy.

More

Swiss businessman gets prison term for asbestos deaths

This content was published on Stephan Schmidheiny has been sentenced to 9 years and 6 months in prison by the Turin Court of Appeal in a case against the former Eternit executive over deaths linked to asbestos exposure in Italy.

Read more: Swiss businessman gets prison term for asbestos deaths
Swiss foreign trade booms in the first quarter

More

Swiss foreign trade booms in the first quarter

This content was published on Swiss imports and exports reached new heights in the first quarter, driven by the chemicals and pharmaceuticals sectors. Shipments to the US rose sharply.

Read more: Swiss foreign trade booms in the first quarter

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR